Denali Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
DNLI$19.85-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities | ||
| Net loss | $(101,802) | $(109,781) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 2,162 | 10,047 |
| Stock–based compensation expense | 27,840 | 28,084 |
| Net amortization of premiums and (discounts) on marketable securities | (10,516) | (7,853) |
| Non-cash adjustment to operating lease expense | (957) | (877) |
| Non-cash gain from divestiture of small molecule programs | (14,537) | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (18,766) | (1,789) |
| Accounts payable | 635 | 3,698 |
| Accruals and other current liabilities | 2,321 | 19,810 |
| Related-party contract liability | — | (141) |
| Net cash used in operating activities | (113,620) | (58,802) |
| Investing activities | ||
| Purchases of marketable securities | (834,157) | (523,714) |
| Purchases of property and equipment | (2,150) | (2,786) |
| Maturities and sales of marketable securities | 383,120 | 433,785 |
| Net cash used in investing activities | (453,187) | (92,715) |
| Financing activities | ||
| Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs of $480K | 499,253 | — |
| Proceeds from exercise of awards under equity incentive plans | 1,022 | 1,604 |
| Net cash provided by financing activities | 500,275 | 1,604 |
| Net decrease in cash, cash equivalents and restricted cash | (66,532) | (149,913) |
| Cash, cash equivalents and restricted cash at beginning of period | 128,681 | 219,544 |
| Cash, cash equivalents and restricted cash at end of period | $62,149 | $69,631 |
| Supplemental disclosures of cash flow information | ||
| Cash paid during the period for income taxes | $— | $4 |
| Equity consideration received in the divestiture of small molecule programs (Note 10) | $15,000 | $— |
| Property and equipment purchases accrued but not yet paid | $1,947 | $6,075 |
| Issuance costs incurred but not yet paid | $394 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.